Kimberly Mullins, NP
Family · Duffield, VANPI 1750725636
Payments from drug & device makers
Across 390 payments — averaging $15.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$965
- Novo Nordisk$888
- AstraZeneca$842
- Lilly USA, LLC$484
- Abbott$410
- Bayer$317
- plus $2K from 29 others
What the payments were for
- Food & beverage$6,004100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 77 | $965 |
| Novo Nordisk | 68 | $888 |
| AstraZeneca | 45 | $842 |
| Lilly USA, LLC | 43 | $484 |
| Abbott | 27 | $410 |
| Bayer | 17 | $317 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $300 |
| Merck | 9 | $159 |
| Amgen(2 entities) | 7 | $154 |
| Amarin Pharma, Inc. | 11 | $138 |
| Johnson & Johnson | 8 | $126 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $122 |
| Otsuka America Pharmaceutical, Inc. | 1 | $122 |
| Corium, LLC | 5 | $118 |
| GSK | 6 | $108 |
| Novartis | 6 | $101 |
| Esperion Therapeutics, Inc. | 5 | $87 |
| Lundbeck LLC | 4 | $82 |
| E.r. Squibb & Sons, L.L.C. | 5 | $80 |
| Sanofi-aventis U.S. LLC | 4 | $63 |
| Pfizer | 3 | $48 |
| Sumitomo Pharma America, Inc. | 3 | $41 |
| Almatica Pharma LLC | 2 | $33 |
| Boehringer Ingelheim | 2 | $31 |
| Impel Pharmaceuticals Inc. | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Mylan Specialty L.p. | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$122
How this compares
$6,004 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 47 | $60,552 |
| LinzessLinaclotide | 90 | $55,024 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $48,283 |
| MounjaroTirzepatide | 41 | $45,413 |
| EliquisApixaban | 60 | $38,547 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 34 | $24,329 |
| RexultiBrexpiprazole | 12 | $17,756 |
| JardianceEmpagliflozin | 22 | $13,368 |
| XareltoRivaroxaban | 13 | $11,036 |
| FarxigaDapagliflozin Propanediol | 17 | $9,321 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $9,267 |
| MovantikNaloxegol Oxalate | 15 | $7,185 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 263 | $7,133 |
| Dexlansoprazole DrDexlansoprazole | 16 | $6,073 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $5,070 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $888 | $60,55247 claims |
| AbbVieLinzess | $965 | $55,02490 claims |
| GSKTrelegy Ellipta | $108 | $48,28357 claims |
| Lilly USA, LLCMounjaro | $484 | $45,41341 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $842 | $42,91784 claims |
| PfizerEliquis | $48 | $38,54760 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $122 | $17,75612 claims |
| Boehringer IngelheimJardiance | $31 | $13,36822 claims |
| Johnson & JohnsonXarelto | $126 | $11,03613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.
Other family in Duffield
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
- Adam MedlinHampton$67K
- Casey SharpDanville$63K
- Norman JacobowitzManassas$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.